Jan-Peter Sowa

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 6

Top Topics

Top Venues

Zeitschrift fur Gastroenterologie

Alimentary pharmacology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Lydia Rohr, Peter Lemmer, Marie Henning, Andrea Tannapfel, Theodor Baars, Paul Manka, Ali Canbay, Jan-Peter Sowa
Patients with NAFLD exhibit more advanced fibrosis in liver biopsy than patients with other chronic liver diseases. Zeitschrift fur Gastroenterologie 61 (1) (2023)
Lydia Rohr, Peter Lemmer, Marie Henning, Andrea Tannapfel, Theodor Baars, Paul Manka, Ali Canbay, Jan-Peter Sowa
Patients with NAFLD exhibit more advanced fibrosis in liver biopsy than patients with other chronic liver diseases. Zeitschrift fur Gastroenterologie 61 (1) (2023)
Anna-Sophia Leven, Robert K Gieseler, Martin Schlattjan, Thomas Schreiter, Marco Niedergethmann, Theodor Baars, Hideo A Baba, Mustafa K Özçürümez, Jan-Peter Sowa, Peter Lemmer
Association of cell death mechanisms and fibrosis in visceral white adipose tissue with pathological alterations in the liver of morbidly obese patients with NAFLD. Adipocyte 10 (1) (2022)
Thomas Schreiter, Robert K Gieseler, Ramiro Vílchez-Vargas, Ruy Jáuregui, Jan-Peter Sowa, Susanne Klein-Scory, Ruth Broering, Roland Siegfried Croner, Jürgen-Walter Treckmann, Alexander Link, Peter Lemmer
Transcriptome-Wide Analysis of Human Liver Reveals Age-Related Differences in the Expression of Select Functional Gene Clusters and Evidence for a PPP1R10-Governed 'Aging Cascade'. Pharmaceutics 13 (12) (2021)
Guillermo Mazzolini, Jan-Peter Sowa, Catalina Atorrasagasti, Özlem Kücükoglu, Wing-Kin Syn, Peter Lemmer
Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 9 (11) (2020)
Peter Lemmer, Nandita Kachru, Jennifer Scarlet Haas, Jan-Peter Sowa, Dominic Meise, Ahmet Burak Ozbay
Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics 52 (7) (2020)